A review of vaccine clinical trials for non-small cell lung cancer

Bibliography

• MOUNTAIN CF: Revisions in the International System for Staging Lung Cancer. Chest (1997) 111(6):1710-1717.
   PubMed Web of Science ®Google Scholar
• KRASNA MJ, REED CE, NUGENT WC et al.: Lung cancer staging and treatment in multidisciplinary trials: cancer and leukaemia group B cooperative group approach. Ann. Thorac. Surg. (1999) 68:201-207.
   PubMed Web of Science ®Google Scholar
• SCHILLER JH, HARRINGTON D, BELANI CP et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. (2002) 346(2):92-98.
   PubMed Web of Science ®Google Scholar
• FOSSELLA F, PEREIRA JR, VON PAWEL J et al.: Randomized, multinational, Phase III study of docetazel plus platinum combinations verses vinorelbine plus cisplatln for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. (2003) 21:3016-3024.
   PubMed Web of Science ®Google Scholar
• SCAGLIOTTI GV, DE MARINIS F, RINALDI M et al.: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. (2002) 20(21):4285-4291.
   PubMed Web of Science ®Google Scholar
• SHANKARAN V, IKEDA H, BRUCE AT et al.: IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogencity. Nature (2001) 410:1107-1111.
   PubMed Web of Science ®Google Scholar
• BELL JW: Possible immune factors in spontaneous regression of bronchogenic carcinoma. Ten year survival in a patient treated with minimal (1,200 r) radiation alone. Am. J. Surg. (1970) 120(6):804-806.
   PubMedGoogle Scholar
• RUCKDESCHEL JC, CODISH SD, STRANAHAN A, MCKNEALLY MF: Postoperative empyema improves survival in lung cancer. Documentation and analysis of a natural experiment. N. Engl. J. Med. (1972) 287(20):1013-1017.
   PubMed Web of Science ®Google Scholar
• WEI YQ, HANG ZB: In situ observation of lymphocyte-tumour cell interaction in human lung carcinoma. Immunol. Invest. (1989) 18(9-10):1095-1105.
   PubMed Web of Science ®Google Scholar
• HANNA N, SHEPHERD FA, FOSSELLA FV et al.: Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. (2004) 22(9):1589-1597.
   PubMed Web of Science ®Google Scholar
• TSAO MS, SAKURADA A, CUTZ JC et al.: Erlotinib in lung cancer – molecular and clinical predictors of outcome. N. Engl. J. Med. (2005) 353(2):133-144.
   PubMed Web of Science ®Google Scholar
• SHEPHERD FA, RODRIGUEZ PEREIRA J, CIULEANU T et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. (2005) 353(2):123-132.
   PubMed Web of Science ®Google Scholar
• KRIS MG, NATALE RB, HERBST RS et al.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA (2003) 290(16):2149-2158.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J: Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev. Vaccines (2005) 4(3):259-274.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, STERMAN D, JABLONS D et al.: Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumour vaccines in non-small-cell lung cancer. J. Natl Cancer Inst. (2004) 96(4):326-331.
   PubMed Web of Science ®Google Scholar
• FAKHRAI H, GRAMATIKOVA S, SAFAEI R: Downregulation of TGF-beta 2 as a therapeutic approach. In: Brain Tumour Immunotherapy. Liau LM, Becker DP, Cloughesy TF, Bigner DD (Eds), Humana Press, Totowa, New Jersey, USA (2001).
   Google Scholar
• DORIGO O, SHAWLER DL, ROYSTON I, SOBOL RE, BEREK JS, FAKHRAI H: Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model. Gynecol. Oncol. (1998) 71(2):204-210.
   PubMed Web of Science ®Google Scholar
• TZAI TS, SHIAU AL, LIU LL, WU CL: Immunization with TGF-beta antisense oligonucleotide-modified autologous tumour vaccine enhances the antitumour immunity of MBT-2 tumour-bearing mice through upregulation of MHC class I and Fas expressions. Anticancer Res. (2000) 20(3A):1557-1562.
   PubMed Web of Science ®Google Scholar
• TZAI TS, LIN CI, SHIAU AL, WU CL: Antisense oligonucleotide specific for transforming growth factor-beta 1 inhibit both in vitro and in vivo growth of MBT-2 murine bladder cancer. Anticancer Res. (1998) 18(3A):1585-1589.
   PubMed Web of Science ®Google Scholar
• MARZO AL, FITZPATRICK DR, ROBINSON BW, SCOTT B: Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res. (1997) 57(15):3200-3207.
   PubMed Web of Science ®Google Scholar
• PARK JA, WANG E, KURT RA, SCHLUTER SF, HERSH EM, AKPORIAYE ET: Expression of an antisense transforming growth factor-beta1 transgene reduces tumorigenicity of EMT6 mammary tumour cells. Cancer Gene Ther. (1997) 4(1):42-50.
   PubMed Web of Science ®Google Scholar
• SALGALLER ML: The development of immunotherapies for non-small cell lung cancer. Expert Opin. Biol. Ther. (2002) 2(3):265-278.
   PubMed Web of Science ®Google Scholar
• RATTO GB, ZINO P, MIRABELLI S et al.: A randomized trial of adoptive immunotherapy with tumour-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma. Cancer (1996) 78(2):244-251.
   PubMed Web of Science ®Google Scholar
• LISSONI P, MEREGALLI S, FOSSATI V et al.: A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin versus chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. Tumouri (1994) 80(6):464-467.
   PubMed Web of Science ®Google Scholar
• RATTO GB, CAFFERATA MA, SCOLARO T et al.: Phase II study of combined immunotherapy, chemotherapy, and radiotherapy in the postoperative treatment of advanced non-small-cell lung cancer. J. Immunother. (2000) 23(1):161-167.
   PubMed Web of Science ®Google Scholar
• RAEZ LE, SANTOS ES, MUDAD R, PODACK ER: Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines. Expert Rev. Anticancer Ther. (2005) 5(4):635-644.
   PubMed Web of Science ®Google Scholar
• O’MAHONY D, KUMMAR S, GUTIERREZ ME: Non-small-cell lung cancer vaccine therapy: a concise review. J. Clin. Oncol. (2005) 23(35):9022-9028.
   PubMed Web of Science ®Google Scholar
• SPARANO JA, DUTCHER JP: Interleukin-2 for the treatment of advanced melanoma. Hematol. Oncol. Ann. (1993) 1(4):279-285.
   Google Scholar
• KIRKWOOD JM, STRAWDERMAN MH, ERNSTOFF MS, SMITH TJ, BORDEN EC, BLUM RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. (1996) 14(1):7-17.
   PubMed Web of Science ®Google Scholar
• WOO EY, CHU CS, GOLETZ TJ et al.: Regulatory CD4(+)CD25(+) T cells in tumours from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. (2001) 61(12):4766-4772.
   PubMed Web of Science ®Google Scholar
• WOO EY, YEH H, CHU CS et al.: Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. (2002) 168(9):4272-4276.
   PubMed Web of Science ®Google Scholar
• SIENEL W, VARWERK C, LINDER A et al.: Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study. Eur. J. Cardiothorac. Surg. (2004) 25(1):131-134.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI K, SPRUILL G, RHODERICK J, SPIELMAN J, SAVARAJ N, PODACK ER: Small cell lung carcinomas express shared and private tumour antigens presented by HLA-A1 or HLA-A2. Cancer Res. (1999) 59(18):4642-4650.
   PubMed Web of Science ®Google Scholar
• WEYNANTS P, THONNARD J, MARCHAND M, DELOS M, BOON T, COULIE PG: Derivation of tumour-specific cytolytic T cell clones from two lung cancer patients with long survival. Am. J. Respir. Crit. Care Med. (1999) 159(1):55-62.
   PubMed Web of Science ®Google Scholar
• BIXBY DL, YANNELLI JR: CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumour-specific cytotoxicity of HLA-A2-positive T cells derived from a normal donor and a patient with non-small cell lung cancer. Int. J. Cancer (1998) 78(6):685-694.
   PubMed Web of Science ®Google Scholar
• YAMADA A, KAWANO K, KOGA M, TAKAMORI S, NAKAGAWA M, ITOH K: Gene and peptide analyses of newly defined lung cancer antigens recognized by HLA-A2402-restricted tumour-specific cytotoxic T lymphocytes. Cancer Res. (2003) 63(11):2829-2835.
   PubMed Web of Science ®Google Scholar
• JIANG F, YIN Z, CARAWAY NP, LI R, KATZ RL: Genomic profiles in stage I primary non small cell lung cancer using comparative genomic hybridization analysis of cDNA microarrays. Neoplasia (2004) 6(5):623-635.
   PubMed Web of Science ®Google Scholar
• MELLONI G, FERRERI AJ, RUSSO V et al.: Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. Oncol. Rep. (2004) 12(1):145-151.
   PubMed Web of Science ®Google Scholar
• NEUNER A, SCHINDEL M, WILDENBERG U, MULEY T, LAHM H, FISCHER JR: Prognostic significance of cytokine modulation in non-small cell lung cancer. Int. J. Cancer (2002) 101(3):287-292.
   PubMed Web of Science ®Google Scholar
• NEUNER A, SCHINDEL M, WILDENBERG U, MULEY T, LAHM H, FISCHER JR: Cytokine secretion: clinical relevance of immunosuppression in non-small cell lung cancer. Lung Cancer (2001) 34(Suppl. 2):S79-S82.
   PubMed Web of Science ®Google Scholar
• DOHADWALA M, LUO J, ZHU L et al.: Non-small cell lung cancer COX-2-dependent invasion is mediated by CD44. J. Biol. Chem. (2001) 276(24):20809-12.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ RH: Models of T cell anergy: is there a common molecular mechanism? J. Exp. Med. (1996) 184(1):1-8.
   PubMed Web of Science ®Google Scholar
• LOMBARDI G, SIDHU S, BATCHELOR R, LECHLER R: Anergic T cells as suppressor cells in vitro. Science (1994) 264(5165):1587-1589.
   PubMed Web of Science ®Google Scholar
• RUFFINI PA, RIVOLTINI L, SILVANI A, BOIARDI A, PARMIANI G: Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol. Immunother. (1993) 36(6):409-416.
   PubMed Web of Science ®Google Scholar
• ROSZMAN T, ELLIOTT L, BROOKS W: Modulation of T cell function by gliomas. Immunol. Today (1991) 12(10):370-374.
   PubMedGoogle Scholar
• SMITH KA: Interleukin-2: inception, impact, and implications. Science (1988) 240(4856):1169-1176.
   PubMed Web of Science ®Google Scholar
• SMITH KA: Lowest dose interleukin-2 immunotherapy. Blood (1993) 81(6):1414-1423.
   PubMed Web of Science ®Google Scholar
• TIGGES MA, CASEY LS, KOSHLAND ME: Mechanism of interleukin-2 signalling: mediation of different outcomes by a single receptor and transduction pathway. Science (1989) 243(4892):781-786.
   PubMed Web of Science ®Google Scholar
• ROOK AH, KEHRL JH, WAKEFIELD LM et al.: Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol. (1986) 136(10):3916-3920.
   PubMed Web of Science ®Google Scholar
• TSUNAWAKI S, SPORN M, DING A, NATHAN C: Deactivation of macrophages by transforming growth factor-beta. Nature (1988) 334(6179):260-262.
   PubMed Web of Science ®Google Scholar
• FONTANA A, FREI K, BODMER S et al.: Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice. J. Immunol. (1989) 143(10):3230-3234.
   PubMed Web of Science ®Google Scholar
• HIRTE HW, CLARK DA, O’CONNELL G, RUSTHOVEN J, MAZURKA J: Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-beta in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody. Cell. Immunol. (1992) 142(1):207-216.
   PubMed Web of Science ®Google Scholar
• RANGES GE, FIGARI IS, ESPEVIK T, PALLADINO MA JR: Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumour necrosis factor alpha. J. Exp. Med. (1987) 166(4):991-998.
   PubMed Web of Science ®Google Scholar
• ANTONIA SJ, SEIGNE J, DIAZ J et al.: Phase I trial of a B7-1 (CD80) gene modified autologous tumour cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J. Urol. (2002) 167(5):1995-2000.
   PubMed Web of Science ®Google Scholar
• HORIG H, LEE DS, CONKRIGHT W et al.: Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother. (2000) 49(9):504-514.
   PubMed Web of Science ®Google Scholar
• HULL GW, MCCURDY MA, NASU Y et al.: Prostate cancer gene therapy: comparison of adenovirus-mediated expression of IL-12 with IL-12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines. Clin. Cancer Res. (2000) 6(10):4101-4109.
   PubMed Web of Science ®Google Scholar
• VON MEHREN M, ARLEN P, TSANG KY et al.: Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res. (2000) 6(6):2219-2228.
   PubMed Web of Science ®Google Scholar
• JOHNSTON JV, MALACKO AR, MIZUNO MT et al.: B7-CD28 costimulation unveils the hierarchy of tumour epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. J. Exp. Med. (1996) 183(3):791-800.
   PubMed Web of Science ®Google Scholar
• LIU B, PODACK ER, ALLISON JP, MALEK TR: Generation of primary tumour-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumours. J. Immunol. (1996) 156(3):1117-1125.
   PubMed Web of Science ®Google Scholar
• NABEL GJ, GORDON D, BISHOP DK et al.: Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc. Natl. Acad. Sci. USA (1996) 93(26):15388-93.
   PubMed Web of Science ®Google Scholar
• RAEZ LE, CASSILETH PA, SCHLESSELMAN JJ et al.: Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (2004) 22(14):2800-2807.
   PubMed Web of Science ®Google Scholar
• MUELLER-PILLASCH F, POHL B, WILDA M et al.: Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech. Dev. (1999) 88(1):95-99.
   PubMed Web of Science ®Google Scholar
• AGUIAR JC, HEDSTROM RC, ROGERS WO et al.: Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device. Vaccine (2001) 20(1-2):275-280.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, MEYERS T, SENZER N et al.: Phase I trial of sequential administration of recombinant DNA and adenoviral expressing L523S protein in early stage non small cell lung cancer (NSCLC). Mol. Ther. (2006) 13(6):1185-1191.
   PubMed Web of Science ®Google Scholar
• RAMOS TC, VINAGERAS E, FERRER MC et al.: Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial. Cancer Biol. Ther. (2006) 5:145-149.
   PubMed Web of Science ®Google Scholar
• GONZALEZ G, CROMBET T, CATALA M et al.: A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann. Oncol. (1998) 9(4):431-435.
   PubMed Web of Science ®Google Scholar
• GONZALEZ G, CROMBET T, TORRES F et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann. Oncol. (2003) 14:461-466.
   PubMed Web of Science ®Google Scholar
• VON EYBEN FE: Epidermal growth factor receptor inhibition and non-small cell lung cancer. Crit. Rev. Clin. Lab. Sci. (2006) 43(4):291-323.
   PubMed Web of Science ®Google Scholar
• HALMOS BH: Lung cancer II. ASCO Annual Meeting Summaries (2006):156-160.
   Google Scholar
• VAN DEN EYNDE BJ, VAN DER BRUGGEN P: T cell defined tumour antigens. Curr. Opin. Immunol. (1997) 9(5):684-693.
   PubMed Web of Science ®Google Scholar
• HERMAN J, VAN DER BRUGGEN P, LUESCHER IF et al.: A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumour cells expressing MAGE3. Immunogenetics (1996) 43(6):377-383.
   PubMed Web of Science ®Google Scholar
• FLEISCHHAUER K, FRUCI D, VAN ENDERT P et al.: Characterization of antigenic peptides presented by HLA-B44 molecules on tumour cells expressing the gene MAGE-3. Int. J. Cancer (1996) 68(5):622-628.
   PubMed Web of Science ®Google Scholar
• TANAKA F, FUJIE T, TAHARA K et al.: Induction of antitumour cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res. (1997) 57(20):4465-4468.
   PubMed Web of Science ®Google Scholar
• KAWASHIMA I, HUDSON SJ, TSAI V et al.: The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various trumor-associated antigens expressed on solid epithelial tumours. Hum. Immunol. (1998) 59:1-14.
   PubMed Web of Science ®Google Scholar
• OISO M, EURA M, KATSURA F et al.: A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes. Int. J. Cancer (1999) 81(3):387-394.
   PubMed Web of Science ®Google Scholar
• TANZARELLA S, RUSSO V, LIONELLO I et al.: Identification of a promiscuous T cell epitope encoded by multiple members of the MAGE family. Cancer Res. (1999) 59(11):2668-2674.
   PubMed Web of Science ®Google Scholar
• RUSSO V, TANZARELLA S, DALERBA P et al.: Dendritic cells acquire the MAGE-3 human tumour antigen from apoptotic cells and induce a class I-restricted T cell response. Proc. Natl. Acad. Sci. USA (2000) 97(5):2185-2190.
   PubMed Web of Science ®Google Scholar
• KEOGH E, FIKES J, SOUTHWOOD S, CELIS E, CHESNUT R, SETTE A: Identification of new epitopes from four different tumour-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J. Immunol. (2001) 167(2):787-796.
   PubMed Web of Science ®Google Scholar
• SCHULTZ ES, CHAPIRO J, LURQUIN C et al.: The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J. Exp. Med. (2002) 195(4):391-399.
   PubMed Web of Science ®Google Scholar
• GAUGLER B, VAN DEN EYNDE B, VAN DER BRUGGEN P et al.: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. (1994) 179(3):921-930.
   PubMed Web of Science ®Google Scholar
• VAN DER BRUGGEN P, BASTIN J, GAJEWSKI T et al.: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumour cells expressing MAGE-3. Eur. J. Immunol. (1994) 24(12):3038-3043.
   PubMed Web of Science ®Google Scholar
• MARCHAND M, VAN BAREN N, WEYNANTS P et al.: Tumour regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer (1999) 80(2):219-230.
   PubMed Web of Science ®Google Scholar
• ATANACKOVIC D, ALTORKI NK, STOCKERT E et al.: Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J. Immunol. (2004) 172:3289-3296.
   PubMed Web of Science ®Google Scholar
• DRANOFF G, JAFFEE E, LAZENBY A et al.: Vaccination with irradiated tumour cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumour immunity. Proc. Natl. Acad. Sci. USA (1993) 90(8):3539-3543.
   PubMed Web of Science ®Google Scholar
• SCHEFFER SR, NAVE H, KORANGY F et al.: Apoptotic but not necrotic, tumour cell vaccines induce a potent immune response in vivo. Int. J. Cancer (2003) 103(2):205-211.
   PubMed Web of Science ®Google Scholar
• BORRELLO I, PARDOLL D: GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev. (2002) 13(2):185-193.
   PubMed Web of Science ®Google Scholar
• JAFFEE EM, THOMAS MC, HUANG AY, HAUDA KM, LEVITSKY HI, PARDOLL DM: Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J. Immunother. Emphasis Tumour Immunol. (1996) 19(3):176-183.
   PubMed Web of Science ®Google Scholar
• COUCH M, SAUNDERS JK, O’MALLEY BW JR, PARDOLL D, JAFFEE E: Genetically engineered tumour cell vaccine in a head and neck cancer model. Laryngoscope (2003) 113(3):552-556.
   PubMed Web of Science ®Google Scholar
• SIMONS JW, MIKHAK B, CHANG JF et al.: Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumour cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. (1999) 59(20):5160-5168.
   PubMed Web of Science ®Google Scholar
• SOIFFER R, LYNCH T, MIHM M et al.: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumour immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA (1998) 95(22):13141-6.
   PubMed Web of Science ®Google Scholar
• SIMONS JW, JAFFEE EM, WEBER CE et al.: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. (1997) 57(8):1537-1546.
   PubMed Web of Science ®Google Scholar
• JAFFEE EM, HRUBAN RH, BIEDRZYCKI B et al.: Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumour vaccine for pancreatic cancer: a Phase I trial of safety and immune activation. J. Clin. Oncol. (2001) 19(1):145-156.
   PubMed Web of Science ®Google Scholar
• SALGIA R, LYNCH T, SKARIN A et al.: Vaccination with irradiated autologous tumour cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumour immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. (2003) 21(4):624-630.
   PubMed Web of Science ®Google Scholar
• SOIFFER R, HODI FS, HALUSKA F et al.: Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumour immunity in patients with metastatic melanoma. J. Clin. Oncol. (2003) 21(17):3343-3350.
   PubMed Web of Science ®Google Scholar
• HARDY S, KITAMURA M, HARRIS-STANSIL T, DAI Y, PHIPPS ML: Construction of adenovirus vectors through Cre-lox recombination. J. Virol. (1997) 71(3):1842-1849.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, JAHAN T, ROSS H et al.: Phase I/2 trial of autologous tumour mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther. (2006) 13(6):555-562.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, DILLMAN RO, SCHWARZENBERGER PO et al.: Phase II study of Lucanix™ (belagenpumatucel) a transforming growth factor 2(TGF-beta 2) antisense gene modified allogeneic tumour cell vaccine in non small cell lung cancer (NSCLC). J. Clin. Oncol. (2006) 24(29):4721-4730.
   PubMed Web of Science ®Google Scholar
• SPORN MB, ROBERTS AB, WAKEFIELD LM, ASSOIAN RK: Transforming growth factor-beta: biological function and chemical structure. Science (1986) 233(4763):532-534.
   PubMed Web of Science ®Google Scholar
• MASSAGUE J: The TGF-beta family of growth and differentiation factors. Cell (1987) 49(4):437-438.
   PubMed Web of Science ®Google Scholar
• BORDER WA, RUOSLAHTI E: Transforming growth factor-beta in disease: the dark side of tissue repair. J. Clin. Invest. (1992) 90(1):1-7.
   PubMed Web of Science ®Google Scholar
• BODMER S, STROMMER K, FREI K et al.: Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J. Immunol. (1989) 143(10):3222-3229.
   PubMed Web of Science ®Google Scholar
• JAKOWLEW SB, MATHIAS A, CHUNG P, MOODY TW: Expression of transforming growth factor beta ligand and receptor messenger RNAs in lung cancer cell lines. Cell Growth Differ. (1995) 6(4):465-476.
   PubMedGoogle Scholar
• CONSTAM DB, PHILIPP J, MALIPIERO UV, TEN DIJKE P, SCHACHNER M, FONTANA A: Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J. Immunol. (1992) 148(5):1404-1410.
   PubMed Web of Science ®Google Scholar
• KONG F, JIRTLE RL, HUANG DH, CLOUGH RW, ANSCHER MS: Plasma transforming growth factor-beta1 level before radiotherapy correlates with long-term outcome of patients with lung carcinoma. Cancer (1999) 86(9):1712-1719.
   PubMed Web of Science ®Google Scholar
• KASID A, BELL GI, DIRECTOR EP: Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J. Immunol. (1988) 141(2):690-698.
   PubMed Web of Science ®Google Scholar
• HIRTE H, CLARK DA: Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor. Cancer Immunol. Immunother. (1991) 32(5):296-302.
   PubMed Web of Science ®Google Scholar
• NAGANUMA H, SASAKI A, SATOH E et al.: Transforming growth factor-beta inhibits interferon-gamma secretion by lymphokine-activated killer cells stimulated with tumour cells. Neurol. Med. Chir. (Tokyo) (1996) 36(11):789-795.
   PubMedGoogle Scholar
• FAKHRAI H, MANTIL JC, LIU L et al.: Phase I clinical trial of a TGF-β antisense-modified tumour cell vaccine in patients with advanced glioma. Cancer Gene Ther. (2006) (In Press).
   PubMedGoogle Scholar
• LIAU LM, FAKHRAI H, BLACK KL: Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene. Neurol Res. (1998) 20(8):742-747.
   PubMed Web of Science ®Google Scholar
• KETTERING JD, MOHAMEDALI AM, GREEN LM, GRIDLEY DS: IL-2 gene and antisense TGF-beta1 strategies counteract HSV-2 transformed tumour progression. Technol. Cancer Res. Treat. (2003) 2(3):211-221.
   PubMed Web of Science ®Google Scholar
• FAKHRAI H, DORIGO O, SHAWLER DL et al.: Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc. Natl. Acad. Sci. USA (1996) 93(7):2909-2914.
   PubMed Web of Science ®Google Scholar
• SHEPHERD FA, DANCEY J, RAMLAU R et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. (2000) 18(10):2095-103.
   PubMed Web of Science ®Google Scholar
• FOSSELLA FV, DEVORE R, KERR RN et al.: Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol. (2000) 18(12):2354-2362.
   PubMed Web of Science ®Google Scholar
• LINK CJ JR, SEREGINA T, ATCHISON R, HALL A, MULDOON R, LEVY JP: Eliciting hyperacute xenograft response to treat human cancer: α(1-3)galactosyltransferase gene therapy. Anticancer Res. (1998) 18:2301-2308.
   Google Scholar
• MORRIS JC, VAHANIAN N, JANIK JE et al.: Phase I study of an antitumour vaccination using α(1,3)galactosyltransferase expressing allogeneic tumour cells in patients (pts) with refractory or recurrent non-small cell lung cancer (NSCLC). J. Clin. Oncol 2005 ASCO Annual Meeting Proceedings (2005) 23(No. 16S, Part I of II [June 1 Suppl.]):2586.
   PubMed Web of Science ®Google Scholar
• VONDERHEIDE RH, HAHN WC, SCHULTZE JL, NADLER LM: The telomerase catalytic subunit is a widely expressed tumour-associated antigen recognized by cytotoxic T lymphocytes. Immunity (1999) 10(6):673-679.
   PubMed Web of Science ®Google Scholar
• MINEV B, HIPP J, FIRAT H, SCHMIDT JD, LANGLADE-DEMOYEN P, ZANETTI M: Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc. Natl. Acad. Sci. USA (2000) 97(9):4796-801.
   PubMed Web of Science ®Google Scholar
• VONDERHEIDE RH, ANDERSON KS, HAHN WC, BUTLER MO, SCHULTZE JL, NADLER LM: Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumour antigen telomerase. Clin. Cancer Res. (2001) 7(11):3343-3348.
   PubMed Web of Science ®Google Scholar
• ARAI J, YASUKAWA M, OHMINAMI H, KAKIMOTO M, HASEGAWA A, FUJITA S: Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukaemia cytotoxic T lymphocytes. Blood (2001) 97(9):2903-2907.
   PubMed Web of Science ®Google Scholar
• HERNANDEZ J, GARCIA-PONS F, LONE YC et al.: Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumour cells. Proc. Natl. Acad. Sci. USA (2002) 99(19):12275-80.
   PubMed Web of Science ®Google Scholar
• SCARDINO A, GROSS DA, ALVES P et al.: HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumour immunotherapy. J. Immunol. (2002) 168(11):5900-5906.
   PubMed Web of Science ®Google Scholar
• GROSS DA, GRAFF-DUBOIS S, OPOLON P et al.: High vaccination efficiency of low-affinity epitopes in antitumour immunotherapy. J. Clin. Invest. (2004) 113(3):425-433.
   PubMed Web of Science ®Google Scholar
• SCHROERS R, HUANG XF, HAMMER J, ZHANG J, CHEN SY: Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T helper cells. Cancer Res. (2002) 62(9):2600-2605.
   PubMed Web of Science ®Google Scholar
• SCHROERS R, SHEN L, ROLLINS L et al.: Human telomerase reverse transcriptase-specific T helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin. Cancer Res. (2003) 9(13):4743-4755.
   PubMed Web of Science ®Google Scholar
• UCHIDA N, OTSUKA T, SHIGEMATSU H et al.: Differential gene expression of human telomerase-associated protein hTERT and TEP1 in human hematopoietic cells. Leuk. Res. (1999) 23(12):1127-1132.
   PubMed Web of Science ®Google Scholar
• TAHARA H, YASUI W, TAHARA E et al.: Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumour and non-tumour tissue sections. Oncogene (1999) 18(8):1561-1567.
   PubMed Web of Science ®Google Scholar
• SHEPHERD F, CARNEY D: Treatment of NSCLC: chemotherapy. In: Textbook of Lung Cancer, IASLC. Hansen Heine H (Ed.), Martin Dunitz, UK (2000):213-242.
   Google Scholar
• BRUNSVIG PF, AAMDAL S, GJERTSEN MK et al.: Telomerase peptide vaccination: a Phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother. (2006) 55(12):1553-1564.
   PubMed Web of Science ®Google Scholar
• GILBOA E, NAIR SK, LYERLY HK: Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol. Immunother. (1998) 46(2):82-87.
   PubMed Web of Science ®Google Scholar
• TIMMERMAN JM, LEVY R: Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. (1999) 50:507-529.
   PubMed Web of Science ®Google Scholar
• CONRAD C, NESTLE FO: Dendritic cell-based cancer therapy. Curr. Opin. Mol. Ther. (2003) 5(4):405-412.
   PubMed Web of Science ®Google Scholar
• KEILHOLZ U, WEBER J, FINKE JH et al.: Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J. Immunother. (2002) 25(2):97-138.
   PubMed Web of Science ®Google Scholar
• CRANMER LD, TREVOR KT, HERSH EM: Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol. Immunother. (2004) 53(4):275-306.
   PubMed Web of Science ®Google Scholar
• HIRSCHOWITZ EA, FOODY T, KRYSCIO R, DICKSON L, STURGILL J, YANNELLI J: Autologous dendritic cell vaccines for non-small-cell lung cancer. J. Clin. Oncol. (2004) 22(14):2808-2815.
   PubMed Web of Science ®Google Scholar
• ZITVOGEL L, REGNAULT A, LOZIER A et al.: Eradication of established murine tumours using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med. (1998) 4:594-600.
   PubMed Web of Science ®Google Scholar
• THERY C, DUBAN L, SEGURA E, VERON P, LANTZ O, AMIGORENA S: Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat. Immunol. (2002) 3:1156-1162.
   PubMed Web of Science ®Google Scholar
• THERY C, REGNAUT A, GARIN J et al.: Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat-shock protein hsc73. J. Cell Biol. (1999) 147:599-610.
   PubMed Web of Science ®Google Scholar
• RAPOSO G, NIJMAN HW, STOORVOGEL W et al.: B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. (1996) 183:1161-1172.
   PubMed Web of Science ®Google Scholar
• DENZER K, VAN EIJK M, KLEIJMEER MJ, JAKOBSON E, DE GROOT C, GEUZE HJ: Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface. J. Immunol. (2000) 65:1259-1265.
   Google Scholar
• HSU DH, PAZ P, VILLAFLOR G et al.: Exosomes as a tumour vaccine: enhancing potency through direct loading of antigenic peptides. J. Immunother. (2003) 26:440-450.
   PubMed Web of Science ®Google Scholar
• MORSE MA, GARST J, OSADA T et al.: A Phase I study of dexosome immunotherapy in patients with advanded non-small cell lung cancer. J. Transl. Med. (2005) 3(1):9.
   PubMed Web of Science ®Google Scholar
• KUFE D, INGHIRAMI G, ABE M, HAYES D, JUSTI-WHEELER H, SCHLOM J: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumours. Hybridoma (1984) 3(3):223-232.
   PubMed Web of Science ®Google Scholar
• BURCHELL J, GENDLER S, TAYLOR-PAPADIMITRIOU J et al.: Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. (1987) 47(20):5476-5482.
   PubMed Web of Science ®Google Scholar
• GENDLER SJ, LANCASTER CA, TAYLOR-PAPADIMITRIOU J et al.: Molecular cloning and expression of human tumour-associated polymorphic epithelial mucin. J. Biol. Chem. (1990) 265(25):15286-15293.
   PubMed Web of Science ®Google Scholar
• LI Y, LIU D, CHEN D, KHARBANDA S, KUFE D: Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene (2003) 22(38):6107-6110.
   PubMed Web of Science ®Google Scholar
• REN J, AGATA N, CHEN D et al.: Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell (2004) 5(2):163-175.
   PubMed Web of Science ®Google Scholar
• MACLEAN GD, REDDISH MA, KOGANTY RR, LONGENECKER BM: Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J. Immunother. Emphasis Tumour Immunol. (1996) 19(1):59-68.
   PubMed Web of Science ®Google Scholar
• BUTTS C, MURRAY N, MAKSYMIUK A et al.: Randomized Phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. (2005) 23(27):6674-6681.
   PubMed Web of Science ®Google Scholar
• KNUTSON KL, SCHIFFMAN K, DISIS ML: Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T cell immunity in cancer patients. J. Clin. Invest. (2001) 107(4):477-484.
   PubMed Web of Science ®Google Scholar
• MARSHALL JL, HOYER RJ, TOOMEY MA et al.: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anticarcinoembryonic antigen immune responses. J. Clin. Oncol. (2000) 18(23):3964-3973.
   PubMed Web of Science ®Google Scholar
• ROSENWIRTH B, KUHN EM, HEENEY JL et al.: Safety and immunogenicity of ALVAC wild type human p53 (vCP207) by the intravenous route in rhesus macaques. Vaccine (2001) 19(13-14):1661-1670.
   PubMed Web of Science ®Google Scholar
• FERRIES E, CONNAN F, PAGES F et al.: Identification of p53 peptides recognized by CD8(+) T lymphocytes from patients with bladder cancer. Hum. Immunol. (2001) 62(8):791-798.
   PubMed Web of Science ®Google Scholar
• TARTAGLIA J, BONNET MC, BERINSTEIN N, BARBER B, KLEIN M, MOINGEON P: Therapeutic vaccines against melanoma and colorectal cancer. Vaccine (2001) 19(17-19):2571-2575.
   PubMed Web of Science ®Google Scholar
• VAN DER BRUGGEN P, TRAVERSARI C, CHOMEZ P et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254(5038):1643-1647.
   PubMed Web of Science ®Google Scholar
• COULIE PG, KARANIKAS V, COLAU D et al.: A monoclonal cytolytic T lymphocyte response observed in a melanoma patient vaccinated with a tumour-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl. Acad. Sci. USA (2001) 98(18):10290-5.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, GODOLPHIN W, JONES LA et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244(4905):707-712.
   PubMed Web of Science ®Google Scholar
• DISIS ML, CALENOFF E, MCLAUGHLIN G et al.: Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. (1994) 54(1):16-20.
   PubMed Web of Science ®Google Scholar
• ZAREMBA S, BARZAGA E, ZHU M, SOARES N, TSANG KY, SCHLOM J: Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. (1997) 57:4570-4577.
   PubMed Web of Science ®Google Scholar
• WENTWORTH PA, VITIELLO A, SIDNEY J et al.: Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur. J. Immunol. (1996) 26(1):97-101.
   PubMed Web of Science ®Google Scholar
• VITIELLO A, MARCHESINI D, FURZE J, SHERMAN LA, CHESNUT RW: Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. (1991) 173(4):1007-1015.
   PubMed Web of Science ®Google Scholar
• MCKINNEY DM, SKVORETZ R, QIN M, ISHIOKA G, SETTE A: Characterization of an in situ IFN-gamma ELISA assay which is able to detect specific peptide responses from freshly isolated splenocytes induced by DNA minigene immunization. J. Immunol. Methods (2000) 237(1-2):105-117.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, NEMUNAITIS J: Granulocyte-macrophage colony-stimulating factor gene-transfected autologous tumour cell vaccine: focus on non-small-cell lung cancer. Clin. Lung Cancer (2003) 5(3):148-157.
   Google Scholar